education
education · EN-US
Retina Synthesis is a data-focused resource exploring therapies in development for retinal diseases.
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Public web form
Booking probability
34%
Guest openness
Selective
Sign up to generate a grounded pitch for Retina Synthesis.
Signup to Generate a PitchRecent episodes include "PRISM at Two Years: The Eye as Biofactory" (30 October 2026, 11 minutes), "Bevacizumab Passes Eylea: How Copay Assistance Rewired Retina Practice" (27 October 2026, 17 minutes), and "Preserving Vision, Not Just Slowing the Lesion: ARCHER II and Vonaprument" (13 October 2026, 26 minutes).
Retina Synthesis publishes roughly weekly, with episodes averaging 18 minutes across 202 episodes.
Booking probability for Retina Synthesis is 34%, and the host is rated Selective on guests. Retina Synthesis requires a Pod Score of 80 or higher. Retina Synthesis's contact route on record: public web form.
The strongest fits for Retina Synthesis are Health & Wellness Services. Retina Synthesis has an education audience.
Retina Synthesis is an education podcast with 202 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #199
Carl Danzig discusses two-year results from PRISM, the Phase 1/2 trial of 4D-150, a single in-office intravitreal gene therapy that turns the retina into a biofactory producing aflibercept and blocking VEGF-C. In...
Anton Kolomeyer walks through Vestrum Health data on intravitreal injection use from 2023 to 2025, presented at ASRS 2026. Bevacizumab climbed to about 30 percent of injections in 2025, passing aflibercept 2 milligrams...
Dr. Ashkan Abbey, Director of Clinical Research at Texas Retina Associates, returns to discuss vonaprument (ANX007), a C1q inhibitor that blocks complement upstream of C3 and C5. In Phase 2 ARCHER, monthly treatment cut...
We welcome back Dr. Roger Goldberg from Bay Area Retina Associates, in our latest episode to discuss the BARDENAS trial (NCT05151744) a global Phase 2 clinical study evaluating the efficacy and safety of vamikibart...
Episode #193
In this episode, we discuss the surgical technique and complications associated with implantation of an encapsulated cell therapy for MacTel 2 with Dr. Lloyd Clark from North Carolina Retina Association.
Episode #192
In this episode, we discuss the results of the Phase 3 Lugano Trial from Eyepoint Pharmaceuticals with Dr. Carl Regillo of Wills Eye Hospital.
In this episode we discuss the use of a subcutaneously administered tyrosine kinase inhibitor migaldendranib (D-4517.2) or MGB for the treatment of neovascular AMD and diabetic macular edema with Dr. Michael Singer from...
Episode #190
In this episode, we review the current status of gene therapy for inherited retinal degenerations with Dr. Ninel Gregori, Professor of Clinical Ophthalmology, Bascom Palmer Eye Institute
In this episode, we discuss the latest developments in faricimab therapy of polypoidal choroidal vasculopathy, with Dr. Gemmy Cheung, Head of the Medical Retina Division, at the Singapore National Eye Center.
Episode #188
In this episode, we review the work of the Research in Safety and Therapeutics (ReST)Committee of the American Society of Retinal Specialists (ASRS) with Dr. Andre Witkin, Chair of the ReST Committee, and Professor of...
In this episode, we discuss potential new treatments for geographic atrophy of age related macular degeneration with Dr. Jessica Randolph of Wagner Kapoor Institute in Richmond, Virginia.
In this episode, we discuss the use of handheld ERG in the evaluating eye with diabetic retinopathy. ERG is a powerful predictive tool in assessing diabetic retinopathy. Our guest is Dr. Raj Maturi of the Midwest Eye...
In this episode, we discuss the long term results of faricimab therapy of neovascular AMD with Dr. Carl Danzig of Fort Lauderdale, Florida and Affiliate Assistant Professor at the Charles Schmidt School of Medicine at...
In this episode, we discuss 5 year results of the GALE study which demonstrated that earlier treatment with pegcetacoplan of geographic atrophy preserves more retinal tissue with Dr. Dilsher Dhoot, California Retina...
Episode #183
In this episode, we discuss the importance of early recognition of PCV, diagnostic techniques, and therapeutic approaches with Professor Jay Chhablani of the University of Pittsburgh.
Episode #182
In this episode, we review the evidence regarding the effectiveness of AREDS vitamin supplementation in affecting the growth of geographic atrophy in age related macular degeneration.
In this episode, we discuss the promising results of intravitreal gene therapy for neovascular AMD with 4D-150 with Dr. Arshad Khanani of Sierra Eye Associates and Clinical Professor of Ophthalmology at the University...
Episode #180
<p>In this episode, we discuss the latest developments in the use of artificial intelligence in home OCT for management of neovascular AMD with Professor Anat Loewenstein of Tel Aviv Medical Center and President...
<p>We discuss long term results of faricimab treatment of DME, with the first author of the Ophthalmology article on the results of Rhone-X trial, Dr. Veeral Sheth, Director of Clinical Research at University Retina in...
<p>In our latest episode we discuss the results of a novel approach to the treatment of geographic atrophy using Xelafaslatide a Fas inhibitor with Dr. David Zacks, Professor of Ophthalmology at the Kellogg Eye Center...
Recent guests on Retina Synthesis. Study who booked and why before you pitch.
head of industry, health & wellness, University of Texas Health Sciences Center
Director of Clinical Research, University Retina
Bay Area Retina Associates
North Carolina Retina Association
PitchCentric classifies Retina Synthesis under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ
